Drug intelligence / Profile preview

ABBV-368 + ABBV-181

Development stage: Unknown
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABBV-368 + ABBV-181 is an investigational combination therapy being studied for the treatment of locally advanced or metastatic solid tumors, including triple negative breast cancer and recurrent/metastatic head and neck squamous cell carcinoma. ABBV-368 is a monoclonal antibody targeting OX40, a co-stimulatory immune checkpoint receptor, intended to enhance anti-tumor immune responses. ABBV-181 (budigalimab) is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to promote T-cell mediated anti-tumor activity. The combination aims to augment anti-tumor immunity by simultaneously increasing T-cell activation (via OX40 stimulation) and blocking immune suppression through PD-1 inhibition. AbbVie is the developer of both agents[1][2][3][8].

Brand names: ABBV-368 + ABBV-181
Other names: ABBV-368 + ABBV-181

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on ABBV-368 + ABBV-181.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-368 + ABBV-181.

Explore the full profile